Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Allocation Concealment in Clinical Trials — Kenneth F. Schulz (2002) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Allocation Concealment in Clinical Trials
Shared by
David Moher
Allocation Concealment in Clinical Trials
Letter
2002
en
Authors
KS
Kenneth F. Schulz
DA
Douglas G. Altman
David Moher
Abstract
1 min read
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2022
Psychopharmacology and Explanatory Pluralism
Awais Aftab
,
Dan Joseph Stein
Letter
2020
The 70/30 Rule Between Men and Women—Disparity or Opportunity?
Aldo Maggioni
,
Susanna Grego
Article
2000
Prostacyclin and Thromboxane and the Development of Preeclampsia
Ariela Benigni
,
Giuseppe Remuzzi
Letter
2009
Adverse Events in Randomized Trials
John P A Ioannidis
Letter
2021
Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied—Reply
Richard A Scolyer
,
Mary‐Ann El Sharouni
,
John F. Thompson
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.